Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.

Ohr M, Kaiser PK.

Expert Opin Pharmacother. 2012 Mar;13(4):585-91. doi: 10.1517/14656566.2012.658368. Epub 2012 Feb 3. Review.

PMID:
22300011
[PubMed - indexed for MEDLINE]
2.

Aflibercept for the treatment of neovascular age-related macular degeneration.

Verner-Cole EA, Davis SJ, Lauer AK.

Drugs Today (Barc). 2012 May;48(5):317-29. doi: 10.1358/dot.2012.48.5.1805931. Review.

PMID:
22645720
[PubMed - indexed for MEDLINE]
3.

Aflibercept for age-related macular degeneration: a game-changer or quiet addition?

Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW.

Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. Review.

PMID:
22813448
[PubMed - indexed for MEDLINE]
4.

Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Frampton JE.

Drugs Aging. 2012 Oct;29(10):839-46. doi: 10.1007/s40266-012-0015-2. Review.

PMID:
23038609
[PubMed - indexed for MEDLINE]
5.

Aflibercept in wet AMD: specific role and optimal use.

Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C.

Drug Des Devel Ther. 2013 Aug 5;7:711-22. doi: 10.2147/DDDT.S40215. eCollection 2013. Review.

PMID:
23990705
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.

Frampton JE.

Drugs Aging. 2013 May;30(5):331-58. doi: 10.1007/s40266-013-0077-9. Review.

PMID:
23539234
[PubMed - indexed for MEDLINE]
7.

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

Ferrara N, Damico L, Shams N, Lowman H, Kim R.

Retina. 2006 Oct;26(8):859-70. Review.

PMID:
17031284
[PubMed - indexed for MEDLINE]
8.

Current therapeutic approaches in neovascular age-related macular degeneration.

Nguyen DH, Luo J, Zhang K, Zhang M.

Discov Med. 2013 Jun;15(85):343-8. Review.

PMID:
23819948
[PubMed - indexed for MEDLINE]
Free Article
9.

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.

Stewart MW.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):103-13. doi: 10.1586/ecp.12.81. Review.

PMID:
23473589
[PubMed - indexed for MEDLINE]
10.

VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.

Dixon JA, Oliver SC, Olson JL, Mandava N.

Expert Opin Investig Drugs. 2009 Oct;18(10):1573-80. doi: 10.1517/13543780903201684. Review.

PMID:
19694600
[PubMed - indexed for MEDLINE]
11.

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Scott AW, Bressler SB.

Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Review.

PMID:
23492430
[PubMed - indexed for MEDLINE]
12.

Neovascular age-related macular degeneration: potential therapies.

Chappelow AV, Kaiser PK.

Drugs. 2008;68(8):1029-36. Review.

PMID:
18484796
[PubMed - indexed for MEDLINE]
13.

Anti-VEGF agents for age-related macular degeneration.

Ozkiris A.

Expert Opin Ther Pat. 2010 Jan;20(1):103-18. doi: 10.1517/13543770902762885. Review.

PMID:
20021287
[PubMed - indexed for MEDLINE]
14.

Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.

Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, Semeraro F.

Curr Drug Targets. 2011 Feb;12(2):149-72. Review.

PMID:
20887246
[PubMed - indexed for MEDLINE]
15.

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.

Mitchell P.

Curr Med Res Opin. 2011 Jul;27(7):1465-75. doi: 10.1185/03007995.2011.585394. Epub 2011 May 31. Review.

PMID:
21623685
[PubMed - indexed for MEDLINE]
16.

Ranibizumab for age-related macular degeneration.

Dhoot DS, Kaiser PK.

Expert Opin Biol Ther. 2012 Mar;12(3):371-81. doi: 10.1517/14712598.2012.660523. Epub 2012 Feb 6. Review.

PMID:
22309606
[PubMed - indexed for MEDLINE]
17.

[Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].

Michels S, Rosenfeld PJ.

Klin Monbl Augenheilkd. 2005 Jun;222(6):480-4. Review. German.

PMID:
15973626
[PubMed - indexed for MEDLINE]
18.

Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.

Mousa SA, Mousa SS.

BioDrugs. 2010 Jun;24(3):183-94. doi: 10.2165/11318550-000000000-00000. Review.

PMID:
20210371
[PubMed - indexed for MEDLINE]
19.

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.

Fong AH, Lai TY.

Clin Interv Aging. 2013;8:467-83. doi: 10.2147/CIA.S36811. Epub 2013 Apr 29. Review.

PMID:
23766636
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Preferred therapies for neovascular age-related macular degeneration.

Lally DR, Gerstenblith AT, Regillo CD.

Curr Opin Ophthalmol. 2012 May;23(3):182-8. doi: 10.1097/ICU.0b013e328352411c. Review.

PMID:
22450218
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk